Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

Background and Aim REGARD and RAINBOW were global, phase 3, randomized, double‐blind trials of second‐line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were described to assess the efficacy and safety of ramucirumab in REGARD and RAINB...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of gastroenterology and hepatology 2018-04, Vol.33 (4), p.814-824
Hauptverfasser:	Muro, Kei, Cho, Jae Yong, Bodoky, Gyorgy, Goswami, Chanchal, Chao, Yee, Santos, Lucas V, Shimada, Yasuhiro, Topuzov, Eldar, Van Cutsem, Eric, Tabernero, Josep, Zalcberg, John, Chau, Ian, Cascinu, Stefano, Cheng, Rebecca, Hsu, Yanzhi, Emig, Michael, Orlando, Mauro, Fuchs, Charles
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Age Age Factors Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical trials Clinical Trials, Phase III as Topic Double-Blind Method elderly Esophagogastric Junction Female Gastric cancer gastroesophageal neoplasms Geriatrics Humans Male Metastases Middle Aged Neoplasm Staging Paclitaxel Paclitaxel - administration & dosage Placebo Effect Ramucirumab Randomized Controlled Trials as Topic Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - pathology Survival Survival Rate Treatment Outcome vascular endothelial growth factor receptor‐2 Young Adult young patients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background and Aim REGARD and RAINBOW were global, phase 3, randomized, double‐blind trials of second‐line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were described to assess the efficacy and safety of ramucirumab in REGARD and RAINBOW in young (≤ 45 and
ISSN:	0815-9319 1440-1746
DOI:	10.1111/jgh.14007